Mizoribine is a synthetic immunosuppressive drug used to aid in the prevention of post-transplant organ rejection. It is used to treat rheumatoid arthritis and other autoimmune diseases, including lupus erythematosus, among others. Its discoverer was Toyama Chemical, and it was approved in Japan in 1984 for use as an immunosuppressant agent. Mizoribine CAS number is 50924-49-7. It has a molecular formula of C9H16N2O6 and a molecular weight of 252.24 g/mol.
Top Ten Keywords from Google and Synonyms
Synonyms of Mizoribine include:
Health Benefits of Mizoribine
Mizoribine is an immunosuppressive agent specifically used to reduce graft rejection in organ transplantation. Mizoribine is also used to alleviate the symptoms of autoimmune disorders such as lupus erythematosus, inflammatory bowel disease, and rheumatoid arthritis. Because of its effects on the immune system, it suppresses the production of immune system cells, preventing their proliferation.
Potential Effects of Mizoribine
Mizoribine’s potential effects are broad, and they vary depending on the physiology of the body. Mizoribine is often used to reduce the risk of complications after organ transplantation. Because it is an immunosuppressive agent, it could help prevent the immune system from attacking and rejecting the transplanted organ.
Mizoribine’s potential effects include its ability to reduce inflammation, which is a characteristic of many autoimmune diseases. It suppresses the development of T and B lymphocytes, preventing their proliferation, and it inhibits the production of cytokines. It also blocks the production of purines, important components of DNA, which inhibits cell growth and proliferation.
Mizoribine’s mechanism of action is based on its ability to inhibit the synthesis of purine RNA and DNA. Specifically, Mizoribine blocks inosine monophosphate dehydrogenase (IMPDH), preventing the synthesis of GTP, a key building block of purine RNA and DNA. Inhibition of GTP production stunts the proliferation of B and T lymphocytes, which are essential immune system components that are responsible for attacking and rejecting transplanted organs.
The immunosuppressive effects of Mizoribine extend beyond its influence on B and T lymphocytes. Mizoribine also inhibits cytokine production, thus reducing the inflammatory signals that contribute to tissue damage seen in autoimmune diseases.
Mizoribine is generally safe, but it can still cause side effects. Clinical trials and reports suggest that long-term use of Mizoribine increases the incidence of bacterial infections, lymphomas, and other malignancies. Mizoribine is also known to cause renal impairment, leading to kidney dysfunction and renal failure.
Side Effects of Mizoribine
Mizoribine could cause side effects such as:
The dosing of Mizoribine varies by the condition being treated. In general, Mizoribine is administered orally in doses ranging from 100-200 milligrams daily. For transplantation, the drug is usually started 2-3 days before the procedure and continued for several weeks or months thereafter.
Mizoribine is an immunosuppressive agent that has been studied extensively and found to be effective at managing the symptoms of autoimmune diseases and preventing transplant rejection. Mizoribine is safe, but it has side effects, many of which are associated with long-term use. Mizoribine would be a useful addition to pharmacotherapy for autoimmune diseases and transplantation. However, patients who require immunosuppression must be closely monitored for signs of bacterial infections and other adverse effects. When Missoribine is used correctly, it has the potential to deliver life-changing outcomes for those afflicted with serious autoimmune conditions or needing transplantation.